Grand Pharmaceutical Group Limited (0512.HK)
HKD 5.76
(-2.54%)
HKD 5.76
(-2.54%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 10.52 Billion HKD | 10.12% |
| 2022 | 9.56 Billion HKD | 11.22% |
| 2021 | 8.59 Billion HKD | 35.34% |
| 2020 | 6.35 Billion HKD | -3.61% |
| 2019 | 6.59 Billion HKD | 10.61% |
| 2018 | 5.95 Billion HKD | 24.89% |
| 2017 | 4.77 Billion HKD | 29.08% |
| 2016 | 3.69 Billion HKD | 13.88% |
| 2015 | 3.24 Billion HKD | 3.95% |
| 2014 | 3.12 Billion HKD | 17.45% |
| 2013 | 2.65 Billion HKD | 29.09% |
| 2012 | 2.05 Billion HKD | 24.99% |
| 2011 | 1.64 Billion HKD | 56.2% |
| 2010 | 1.05 Billion HKD | 93.38% |
| 2009 | 545.43 Million HKD | 102.1% |
| 2008 | 269.88 Million HKD | 450.27% |
| 2007 | 49.04 Million HKD | 15.65% |
| 2006 | 42.4 Million HKD | -8.57% |
| 2005 | 46.38 Million HKD | -26.56% |
| 2004 | 63.16 Million HKD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 6.04 Billion HKD | 0.0% |
| 2023 FY | 10.52 Billion HKD | 10.12% |
| 2023 Q2 | 5.98 Billion HKD | 0.0% |
| 2023 Q4 | 4.54 Billion HKD | 0.0% |
| 2022 FY | 9.56 Billion HKD | 11.22% |
| 2022 Q2 | 5.21 Billion HKD | 0.0% |
| 2022 Q4 | 4.34 Billion HKD | 0.0% |
| 2021 Q4 | 4.03 Billion HKD | 0.0% |
| 2021 FY | 8.59 Billion HKD | 35.34% |
| 2021 Q2 | 4.56 Billion HKD | 0.0% |
| 2020 Q4 | 3.09 Billion HKD | 0.0% |
| 2020 Q2 | 3.25 Billion HKD | 0.0% |
| 2020 FY | 6.35 Billion HKD | -3.61% |
| 2019 Q4 | 3 Billion HKD | 0.0% |
| 2019 FY | 6.59 Billion HKD | 10.61% |
| 2019 Q2 | 3.58 Billion HKD | 0.0% |
| 2018 FY | 5.95 Billion HKD | 24.89% |
| 2018 Q2 | 3.23 Billion HKD | 0.0% |
| 2018 Q4 | 2.72 Billion HKD | 0.0% |
| 2017 FY | 4.77 Billion HKD | 29.08% |
| 2017 Q2 | 2.27 Billion HKD | 0.0% |
| 2017 Q4 | 2.49 Billion HKD | 0.0% |
| 2016 Q4 | 1.91 Billion HKD | 0.0% |
| 2016 Q2 | 1.78 Billion HKD | 0.0% |
| 2016 FY | 3.69 Billion HKD | 13.88% |
| 2015 Q4 | 1.66 Billion HKD | 0.0% |
| 2015 Q2 | 1.57 Billion HKD | 0.0% |
| 2015 FY | 3.24 Billion HKD | 3.95% |
| 2014 Q4 | 1.49 Billion HKD | 0.0% |
| 2014 Q2 | 1.62 Billion HKD | 0.0% |
| 2014 FY | 3.12 Billion HKD | 17.45% |
| 2013 Q4 | 1.33 Billion HKD | 0.0% |
| 2013 FY | 2.65 Billion HKD | 29.09% |
| 2013 Q2 | 1.32 Billion HKD | 0.0% |
| 2012 Q2 | 514.82 Million HKD | 0.0% |
| 2012 FY | 2.05 Billion HKD | 24.99% |
| 2012 Q4 | 664.57 Million HKD | 29.09% |
| 2012 Q3 | 514.82 Million HKD | 0.0% |
| 2012 Q1 | 514.82 Million HKD | 0.0% |
| 2011 Q2 | 411.89 Million HKD | 0.0% |
| 2011 Q3 | 411.89 Million HKD | 0.0% |
| 2011 Q4 | 514.82 Million HKD | 24.99% |
| 2011 FY | 1.64 Billion HKD | 56.2% |
| 2011 Q1 | 411.89 Million HKD | 0.0% |
| 2010 Q1 | 263.68 Million HKD | 0.0% |
| 2010 Q3 | 263.68 Million HKD | 0.0% |
| 2010 Q4 | 411.89 Million HKD | 56.2% |
| 2010 FY | 1.05 Billion HKD | 93.38% |
| 2010 Q2 | 263.68 Million HKD | 0.0% |
| 2009 Q1 | 136.35 Million HKD | 0.0% |
| 2009 Q3 | 136.35 Million HKD | 0.0% |
| 2009 Q4 | 263.68 Million HKD | 93.38% |
| 2009 FY | 545.43 Million HKD | 102.1% |
| 2009 Q2 | 136.35 Million HKD | 0.0% |
| 2008 Q2 | 67.47 Million HKD | 0.0% |
| 2008 Q4 | 136.35 Million HKD | 102.1% |
| 2008 Q1 | 67.47 Million HKD | 0.0% |
| 2008 FY | 269.88 Million HKD | 450.27% |
| 2008 Q3 | 67.47 Million HKD | 0.0% |
| 2007 Q1 | 12.26 Million HKD | 0.0% |
| 2007 Q4 | 67.47 Million HKD | 450.27% |
| 2007 Q3 | 12.26 Million HKD | 0.0% |
| 2007 Q2 | 12.26 Million HKD | 0.0% |
| 2007 FY | 49.04 Million HKD | 15.65% |
| 2006 Q4 | 12.26 Million HKD | 15.65% |
| 2006 FY | 42.4 Million HKD | -8.57% |
| 2006 Q2 | 10.6 Million HKD | 0.0% |
| 2006 Q3 | 10.6 Million HKD | 0.0% |
| 2006 Q1 | 10.6 Million HKD | 0.0% |
| 2005 Q2 | 11.59 Million HKD | 0.0% |
| 2005 Q4 | 10.6 Million HKD | -8.57% |
| 2005 FY | 46.38 Million HKD | -26.56% |
| 2005 Q1 | 11.59 Million HKD | 0.0% |
| 2005 Q3 | 11.59 Million HKD | 0.0% |
| 2004 Q2 | 15.79 Million HKD | 0.0% |
| 2004 Q3 | 15.79 Million HKD | 0.0% |
| 2004 Q1 | 15.79 Million HKD | 0.0% |
| 2004 Q4 | 11.59 Million HKD | -26.56% |
| 2004 FY | 63.16 Million HKD | 0.0% |
| 2003 Q4 | 15.79 Million HKD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -3963.0% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -17717.168% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -1243.264% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | -995.359% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | -899.929% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | -517.008% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -1201.384% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -2488.019% |
| SSY Group Limited | 6.46 Billion HKD | -62.921% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -1523.897% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | -617.373% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 96.106% |